Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 7,051 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Chronic Rhinosinusitis Without Nasal Polyps
Interventions: Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: Birmingham, Alabama • La Jolla, California • Murrieta, California + 7 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg, Placebo - 100 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 16 more

Conditions: Chronic Obstructive Pulmonary Disease, COPD
Interventions: Tiotropium, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 35 Years to 85 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: COVID-19
Interventions: Baricitinib, Dexamethasone, Placebo, Remdesivir; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 1,010 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 61
States / cities: Birmingham, Alabama • Fresno, California • La Jolla, California + 50 more

Conditions: Cough, Refractory Chronic Cough
Interventions: BLU-5937, Placebo; Drug
Lead sponsor: Bellus Health Inc. - a GSK company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 957 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 67
States / cities: Jasper, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 59 more

Conditions: Safety Issues
Interventions: TAF/EVG vaginal insert, Matching Placebo vaginal insert; Drug
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Bullous Pemphigoid
Interventions: QGE031, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 20 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Iowa City, Iowa • Durham, North Carolina

Conditions: Sarcoidosis, Pulmonary
Interventions: Namilumab, Placebo; Drug
Lead sponsor: Kinevant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 24
States / cities: Birmingham, Alabama • Palo Alto, California • Valencia, California + 21 more

Conditions: Opioid Use Disorder, Cannabis Use
Interventions: Cannabis, Placebo Cannabis, Intranasal Opioid Agonist, Oral Opioid Agonist; Drug
Lead sponsor: Shanna Babalonis, PhD; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Healthy Participants
Interventions: AZD6234, Placebo, Acetaminophen; Drug · Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 10773 placebo, BI 10773 low dose, BI 10773 high dose; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 56
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more

Conditions: Polymyalgia Rheumatica
Interventions: Sarilumab SAR153191 (REGN88), Sarilumab-matching placebo, Prednisone, Prednisone-matching placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 10
States / cities: Upland, California • Denver, Colorado • Stamford, Connecticut + 7 more

Conditions: Migraine
Interventions: Omega 3 Polyunsaturated Fats, Matching Placebo; Dietary Supplement · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 10 Years to 17 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Low Back Pain
Interventions: Acetaminophen, Ibuprofen 600 mg, Educational intervention, Placebo oral capsule; Drug · Behavioral
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 69 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: TAK-875, Glimepiride, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 64
States / cities: Birmingham, Alabama • Hoover, Alabama • Tucson, Arizona + 61 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: olaparib, abiraterone acetate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 895 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 28
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 23 more

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: AR11, Placebo; Drug
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 7
States / cities: Bradenton, Florida • Maitland, Florida • South Miami, Florida + 3 more

Conditions: Paroxysmal Atrial Fibrillation
Interventions: FlecIH-103; Drug
Lead sponsor: InCarda Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 18
States / cities: Davis, California • Long Beach, California • Bridgeport, Connecticut + 12 more

Conditions: Alzheimer Disease
Interventions: neflamapimod, placebo; Drug · Other
Lead sponsor: EIP Pharma Inc; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 16
States / cities: Long Beach, California • San Diego, California • Santa Ana, California + 13 more

Conditions: Major Depressive Disorder (MDD)
Interventions: Ropanicant, Placebo; Drug
Lead sponsor: Suven Life Sciences Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 35
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 31 more

Conditions: Binge Drinking
Interventions: Alcohol vs. Placebo; Other
Lead sponsor: Baylor University; Other
Eligibility: 21 Years to 40 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Schizophrenia
Interventions: Lurasidone, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 22
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 16 more

Conditions: Chronic Spontaneous Urticaria
Interventions: barzolvolimab, Matching Placebo; Biological · Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 13
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 10 more

Search by objective public record fields.

A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation

Adaptive COVID-19 Treatment Trial 4 (ACTT-4)

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Safety and PK Multi-dose Study of TAF/EVG Vaginal Insert

Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment

A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis

Cannabis Effects on Opioid Self-Administration

Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

Omega-3 Supplementation for Pediatric Migraine

Ibuprofen With or Without Acetaminophen for Low Back Pain

Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting

Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation

Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease

Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

Alcohol and Neural Cardiovascular Control in Binge Drinkers

A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia

A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria